Q-omics provides the consensus-scored ABCC12 profile across patient tissues and cancer cell-line models. ABCC12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ABCC12 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, ABCC12 RNA expression shows 14,319 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, BRCA, and TGCT as cancer lineages where ABCC12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABCC12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABCC12 survival associations across molecular data types. ABCC12 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABCC12 RNA expression–survival associations across cancer types. High ABCC12 expression shows unfavorable associations in KIRC, BLCA, UVM and CESC, but favorable associations in LUAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ABCC12 RNA expression.
This table summarizes ABCC12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ABCC12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABCC12 shows lower tumor expression in LUSC, LUAD and ESCA and higher tumor expression in BRCA, THCA and UCEC. The BRCA box plot shows higher ABCC12 RNA expression in tumor versus normal tissue (log2 FC = +0.255, t-test p = .010).
This table shows molecular features associated with ABCC12 in patient tissues and cancer cell lines. In patient samples, ABCC12 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ABCC12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
